- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01072695
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)
This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA in adults with chronic Hepatitis C virus (HCV). In Part A, approximately thirty (30) subjects 18-70 years of age who meet study entry criteria will be randomized (in other words, selected at random, like flipping a coin) to one of the two treatment groups (GS-9256 plus GS-9190 or GS-9256 plus GS-9190 plus RIBA). In Part B, an additional fifteen (15) subjects will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).
Following randomization, subjects will return for a Baseline (Day 1) visit, at which time study medication will be dispensed and subjects will enter a 28 day treatment phase. During the treatment phase, subjects will receive oral study drugs twice daily for 28 days and PEG once weekly for Part B. Subjects then receive PEG/RIBA as local SOC starting on Day 28 (not provided as part of the study). Following completion of the 28-day treatment phase, subjects will be followed for approximately 72 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
GS-9256 (an HCV NS3 protease inhibitor) plus GS-9190 (non-nucleoside HCV NS5B inhibitor) will be administered for 28 days with and without RIBA (weight-based dosing) and with PEG/RIBA in treatment-naïve subjects with chronic genotype 1 HCV infection. In Part A, thirty (30) subjects with genotype 1 will be randomized to 75 mg GS-9256 BID plus 40 mg GS-9190 BID or 75 mg GS-9256 BID plus 40 mg GS-9190 BID plus RIBA 1000-1200 mg/day for 28 days. In Part B, an additional fifteen (15) subjects with genotype 1 will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA for 28 days. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).
In Part A, for any subjects meeting pre-defined, individual, virologic criteria, PEG/RIBA standard of care will be started prior to Day 28.
Both PEG and RIBA will be administered at their currently approved dosages for treatment of HCV infection in accordance with appropriate labeling. Subjects will be monitored for safety (including ECG monitoring), antiviral activity, pharmacokinetics, and resistance 2-3 times weekly through Day 28.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
-
Brussels, Belgia, 1200
-
Bruxelles, Belgia, 1070
-
-
-
-
-
Clichy, Frankrike, 92110
-
La Tronche, Frankrike, 38700
-
Paris, Frankrike, 75475
-
-
-
-
-
London, Storbritannia, SE5 9RS
-
London, Storbritannia, E1 2AT
-
-
-
-
-
Duesseldorf, Tyskland, 40237
-
Frankfurt, Tyskland, 60590
-
Hamburg, Tyskland, 20099
-
Hannover, Tyskland, 30625
-
Wurzburg, Tyskland, 97080
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adult subjects, ages 18-70
- Willing able to provide informed consent
- BMI between 18 and 36 kg/m2 (inclusive)
- Chronic HCV infection, genotype 1
- HCV RNA >/= 3 log, but < 7.2 log10 IU/ml at screen
- Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis
- HCV treatment naïve with imminent plans to start treatment with PEG/RIBA
- QTcF </= 450 msec at screen
- ALT, AST, GGT < 5 X ULN at the screening visit
- Creatinine clearance >= 50 mL/min
- Absolute neutrophil count >= 1500/mm3
- Hemoglobin >/= 12 g/dL (female), >/= 13 g/dL (male)
- Males agree to use of effective contraception and refrain from sperm donation
- Able to comply with dosing instructions and study visits
- Of generally good health
Exclusion Criteria:
- Females of child-bearing potential or males with female partners who are pregnant or planning to become pregnant
- Infection with other HCV genotype or multiple HCV genotypes
- Poorly controlled diabetes
- Hemoglobinopathy or known retinal disease
- History of sarcoidosis or invasive malignancy
- Untreated or significant psychiatric illness
- Co-infection with hepatitis B virus or human immunodeficiency virus
- Chronic use of systemic immunosuppressive agents
- Autoimmune disorders
- Severe COPD
- History of significant cardiac disease
- Known cirrhosis
- Non-HCV chronic liver disease
- Transplantation
- Suspicion of hepatocellular carcinoma
- Bilirubin above the normal range or Gilbert's syndrome
- Decompensated liver disease
- Clinically significant illness
- GI disease that could interfere with absorption
- Acute porphyria
- Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males or current binge drinking
- Positive urine drug screen
- History of difficult blood collection
- Significant recent blood loss
- Prohibited medications, including H2 antagonists, investigational agents
- Restricted fruits, fruit juices
- Hypersensitivity
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Arm 1
|
75 mg BID x 28 days
40 mg BID x 28 days
|
Eksperimentell: Arm 2
|
75 mg BID x 28 days
40 mg BID x 28 days
1000-1200 mg/day given BID
Andre navn:
|
Eksperimentell: Arm 3
|
75 mg BID x 28 days
40 mg BID x 28 days
1000-1200 mg/day given BID
Andre navn:
180 ug q week
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of subjects achieving rapid virologic response (RVR)
Tidsramme: Day 28
|
Day 28
|
AEs, physical examination and clinical laboratory test findings, vital signs, ECGs
Tidsramme: Throughout first six weeks of study
|
Throughout first six weeks of study
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Plasma pharmacokinetics
Tidsramme: Throughout Day 28
|
Throughout Day 28
|
Viral resistance
Tidsramme: Throughout study
|
Throughout study
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Juan Betular, Gilead Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Patologiske prosesser
- RNA-virusinfeksjoner
- Blodbårne infeksjoner
- Sykdomsattributter
- Leversykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Infeksjoner
- Smittsomme sykdommer
- Hepatitt
- Hepatitt C
- Virussykdommer
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Antimetabolitter
- Ribavirin
- Peginterferon alfa-2a
Andre studie-ID-numre
- GS-US-196-0112
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HCV-infeksjon
-
Ascletis Pharmaceuticals Co., Ltd.Fullført
-
Ain Shams UniversityFullført
-
PfizerFullført
-
Bristol-Myers SquibbFullførtHCV (genotype 1)Forente stater, Puerto Rico
-
Valme University HospitalBoehringer IngelheimUkjentHCV-infeksjon. | HCV viral belastning.Spania
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Rekruttering
-
Tibotec Pharmaceuticals, IrelandFullført
-
Kirby InstituteAustralasian Society for HIV Viral Hepatitis and Sexual Health Medicine... og andre samarbeidspartnereRekruttering
-
Radboud University Medical CenterTilbaketrukketHCVNederland, Tyskland
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Fullført
Kliniske studier på GS-9256
-
Gilead SciencesFullførtKronisk hepatitt C-infeksjonForente stater, Spania, Storbritannia, Canada, Tyskland, Frankrike, Østerrike, Polen, Belgia, Tsjekkisk Republikk, Italia
-
Gilead SciencesFullførtHCV-infeksjonForente stater, Nederland, Tyskland
-
Gilead SciencesFullførtIkke-alkoholisk SteatohepatittForente stater, Frankrike
-
Gilead SciencesAktiv, ikke rekrutterendeKronisk hepatitt BTaiwan, New Zealand
-
Gilead SciencesFullførtKjønnsvorterForente stater
-
Gilead SciencesOno Pharmaceutical Co. Ltd; Galapagos NVFullførtSjøgrens syndromForente stater, Spania, Storbritannia, Polen
-
Gilead SciencesFullførtHepatitt C virusinfeksjonForente stater, Frankrike, Storbritannia, Tyskland, Canada, Australia, New Zealand, Puerto Rico
-
Gilead SciencesFullførtHepatitt C virusinfeksjonForente stater, Frankrike, Storbritannia, Tyskland, Australia, Canada, New Zealand, Puerto Rico
-
Gilead SciencesAvsluttetAvanserte solide svulsterForente stater
-
Gilead SciencesFullførtRSV-infeksjonForente stater